Madrigal Pharmaceuticals (MDGL) Projected to Post Earnings on Wednesday

Madrigal Pharmaceuticals (NASDAQ:MDGL) is expected to issue its quarterly earnings data before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($4.27) per share and revenue of $98.53 million for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Madrigal Pharmaceuticals Stock Performance

Shares of Madrigal Pharmaceuticals stock opened at $339.87 on Wednesday. Madrigal Pharmaceuticals has a 12 month low of $189.00 and a 12 month high of $368.29. The firm has a market capitalization of $7.41 billion, a P/E ratio of -13.55 and a beta of -0.38. The company has a current ratio of 5.98, a quick ratio of 5.93 and a debt-to-equity ratio of 0.15. The business has a fifty day simple moving average of $316.98 and a two-hundred day simple moving average of $279.75.

Wall Street Analysts Forecast Growth

MDGL has been the topic of several research reports. Oppenheimer dropped their price objective on shares of Madrigal Pharmaceuticals from $375.00 to $350.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. JMP Securities reissued a “market outperform” rating and issued a $427.00 price target on shares of Madrigal Pharmaceuticals in a research report on Friday, January 10th. UBS Group raised their price objective on Madrigal Pharmaceuticals from $411.00 to $441.00 and gave the company a “buy” rating in a research report on Friday, November 1st. B. Riley boosted their target price on Madrigal Pharmaceuticals from $194.00 to $236.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Finally, HC Wainwright raised their price target on Madrigal Pharmaceuticals from $390.00 to $400.00 and gave the company a “buy” rating in a report on Tuesday, January 14th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $351.67.

Insiders Place Their Bets

In other Madrigal Pharmaceuticals news, CEO William John Sibold sold 1,584 shares of the company’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $335.24, for a total transaction of $531,020.16. Following the completion of the sale, the chief executive officer now owns 54,303 shares in the company, valued at $18,204,537.72. This represents a 2.83 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Robert E. Waltermire sold 103 shares of Madrigal Pharmaceuticals stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $335.24, for a total value of $34,529.72. Following the completion of the transaction, the vice president now owns 4,955 shares in the company, valued at $1,661,114.20. This trade represents a 2.04 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 12,090 shares of company stock valued at $3,883,621 over the last ninety days. 22.80% of the stock is owned by insiders.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.